Stryker Corporation announced that results from the Wingspan StEnt System Post MArket SurVEillance Study presented at the International Stroke Conference, providing compelling evidence that more patients suffering from intracranial atherosclerotic disease may benefit from endovascular treatment with the Wingspan Stent System. Results from this FDA-mandated post-market surveillance trial showed that patients receiving on-label treatment with the Wingspan Stent System demonstrated a 2.6% observed rate of stroke or death, compared to the pre-specified rate for early success, which was established as 4.0% with a minimum 150 patients. These results are significant when compared to the study's null hypothesis with high predictive probability (>95%) that the true rate is 9.7%, and suggest that endovascular treatment of ICAD patients receiving on-label use of the Wingspan Stent may provide promising results. Stryker's sponsored WEAVE Trial is a multi-center, prospective, post-market surveillance study designed to evaluate the rate of stroke or death within 72 hours of the procedure in patients treated with the Wingspan Stent System. Stryker and the WEAVE investigators believe the final results from the trial may lead to a critical shift in how physicians approach patient selection for endovascular therapy for ICAD. The endovascular treatment success rate shown for on-label patients in the WEAVE Trial is compelling and a considerable development beyond what has been shown in previously reported trials. The WEAVE Trial represents an important milestone in the treatment of ICAD, yet there is still significant work required to ensure patients with ICAD receive optimal treatment. Best outcomes may be achieved when patients are treated on-label.